List A - Search Results

1

Pretransplantation 5-azacitidine in high-risk myelodysplastic syndrome.

Nishihori T, Perkins J, Mishra A, Komrokji R, Kim J, Kharfan-Dabaja MA, Perez L, Lancet J, Fernandez H, List A, Anasetti C, Field T. Nishihori T, et al. Among authors: list a. Biol Blood Marrow Transplant. 2014 Jun;20(6):776-80. doi: 10.1016/j.bbmt.2014.02.008. Epub 2014 Feb 15. Biol Blood Marrow Transplant. 2014. PMID: 24534108 Free article. Clinical Trial.

2

Myelodysplastic syndromes.

List AF, Vardiman J, Issa JP, DeWitte TM. List AF, et al. Hematology Am Soc Hematol Educ Program. 2004:297-317. doi: 10.1182/asheducation-2004.1.297. Hematology Am Soc Hematol Educ Program. 2004. PMID: 15561689 Review.

3

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, Greenberg P, Thomas D, Stone R, Reeder C, Wride K, Patin J, Schmidt M, Zeldis J, Knight R; Myelodysplastic Syndrome-003 Study Investigators. List A, et al. N Engl J Med. 2006 Oct 5;355(14):1456-65. doi: 10.1056/NEJMoa061292. N Engl J Med. 2006. PMID: 17021321 Free article. Clinical Trial.

4

Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors.

Epling-Burnette PK, Bai F, Painter JS, Rollison DE, Salih HR, Krusch M, Zou J, Ku E, Zhong B, Boulware D, Moscinski L, Wei S, Djeu JY, List AF. Epling-Burnette PK, et al. Blood. 2007 Jun 1;109(11):4816-24. doi: 10.1182/blood-2006-07-035519. Epub 2007 Mar 6. Blood. 2007. PMID: 17341666 Free PMC article.

5

Immunomodulatory therapy for myelodysplastic syndromes.

Sokol L, List AF. Sokol L, et al. Int J Hematol. 2007 Nov;86(4):301-5. doi: 10.1532/IJH97.06063. Int J Hematol. 2007. PMID: 18055335

6

Targeted therapies in myelodysplastic syndrome.

Melchert M, List A. Melchert M, et al. Among authors: list a. Semin Hematol. 2008 Jan;45(1):31-8. doi: 10.1053/j.seminhematol.2007.10.001. Semin Hematol. 2008. PMID: 18179967

7

Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs.

Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA, Edwards BK, List AF. Rollison DE, et al. Among authors: list af. Blood. 2008 Jul 1;112(1):45-52. doi: 10.1182/blood-2008-01-134858. Epub 2008 Apr 28. Blood. 2008. PMID: 18443215 Free article.

8

Treatment strategies to optimize clinical benefit in the patient with myelodysplastic syndromes.

List AF. List AF. Cancer Control. 2008 Oct;15 Suppl:29-39. doi: 10.1177/107327480801504s04. Cancer Control. 2008. PMID: 18813207 Free article.

9

A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia.

Lancet JE, Baer MR, Duran GE, List AF, Fielding R, Marcelletti JF, Multani PS, Sikic BI. Lancet JE, et al. Leuk Res. 2009 Aug;33(8):1055-61. doi: 10.1016/j.leukres.2008.09.015. Epub 2008 Dec 23. Leuk Res. 2009. PMID: 19108889 Clinical Trial.

10

Outcome of patients with myelodysplastic syndromes in the Veterans Administration population.

Komrokji RS, Matacia-Murphy GM, Al Ali NH, Beg MS, Safa MM, Rollison DE, List AF. Komrokji RS, et al. Leuk Res. 2010 Jan;34(1):59-62. doi: 10.1016/j.leukres.2009.03.022. Epub 2009 Apr 14. Leuk Res. 2010. PMID: 19368972

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

495 results

Search Page

Filters